E8001
/ Eisai
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 21, 2026
Quantification of PEG2000-DMG and TS-202, an ionic lipid, in rabbit plasma by LC-MS/MS: Application to complement C5 siRNA lipid nanoparticles.
(PubMed, J Pharm Biomed Anal)
- "A simple and robust assay was developed for the quantification of PEG2000-DMG and TS-202, key components of the lipid nanoparticle (LNP) formulation of E8001-LNP, which encapsulates small-interfering RNA targeting complement C5, in rabbit plasma...Detection was performed using selected reaction monitoring in positive ion mode, with mass transitions of m/z 780.8 → 698.9 for PEG2000-DMG and m/z 650.5 → 126.3 for TS-202...Application to a toxicokinetic study in rabbits revealed that PEG2000-DMG was eliminated much faster than TS-202. The incurred sample reanalysis further confirmed the assay reproducibility."
Journal • Preclinical
September 25, 2023
A Study to Assess the Safety and Tolerability of E8001 in Healthy Male Participants
(clinicaltrials.gov)
- P1 | N=36 | Completed | Sponsor: Eisai Co., Ltd. | Active, not recruiting ➔ Completed
Trial completion
March 30, 2023
A Study to Assess the Safety and Tolerability of E8001 in Healthy Male Participants
(clinicaltrials.gov)
- P1 | N=36 | Active, not recruiting | Sponsor: Eisai Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed
August 04, 2022
A Study to Assess the Safety and Tolerability of E8001 in Healthy Male Participants
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Eisai Co., Ltd. | Trial completion date: Sep 2022 ➔ Sep 2023 | Trial primary completion date: Sep 2022 ➔ Sep 2023
Trial completion date • Trial primary completion date
1 to 4
Of
4
Go to page
1